Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as biphasic human insulin, biphasic human insulin 50
biphasic human insulin 30 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Formulation A | EXPERIMENTAL | - |
| Formulation B | ACTIVE_COMPARATOR | - |
| NN2000 | EXPERIMENTAL | - |
| NN-X14 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| biphasic human insulin 30 | DRUG | Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits |
Inclusion Criteria: * Considered generally healthy upon completion of medical history and physical examination as judged by the Investigator * Body Mass Index (BMI) between 18.0 and 27.0 kg/m\^2, inclusive * Non-smoker, defined as no nicotine consumption for at least one year * Fasting plasma gluco...
Biphasic human insulin 30 is an insulin-based therapy developed by Novo Nordisk A/S for diabetes. It is a small molecule that acts as an agonist at the insulin receptor (INSR). It is also known as biphasic human insulin and biphasic human insulin 50. It is in Phase 1 clinical development.
Biphasic human insulin 30 is being developed for the treatment of diabetes. It is a metabolic therapy that combines insulin action through the insulin receptor. Development is at the Phase 1 stage, and it has been studied in two completed clinical trials in Japan and Germany.
Biphasic human insulin 30 targets the insulin receptor, or INSR. It acts as an agonist at this receptor, meaning it activates insulin receptor signaling. This mechanism underlies its development as a diabetes therapy. The drug is a small molecule being developed by Novo Nordisk A/S.
Biphasic human insulin 30 is developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the clinical program for this diabetes candidate. The drug is also referred to as biphasic human insulin and biphasic human insulin 50.
Biphasic human insulin 30 is in Phase 1 clinical development. It is investigational and has not been approved. Two Phase 1 trials have been completed, with no active trials ongoing. The completed studies enrolled a total of 79 participants and were randomized, double-blind, and active-controlled.
Biphasic human insulin 30 has been studied in two completed Phase 1 trials. NCT01620450 compared insulin aspart produced by two processes in healthy Japanese participants, enrolling 34. NCT01486888 assessed bioequivalence of two Mixtard 30 formulations in healthy subjects in Germany, enrolling 45. Both trials are completed.
Biphasic human insulin 30 is also known as biphasic human insulin and biphasic human insulin 50. These names refer to the same Novo Nordisk A/S diabetes program. The drug targets the insulin receptor (INSR) as an agonist and is in Phase 1 development.